NCT00276757 · CITED IN SOURCE DOCUMENTS

Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase: NA
Status at capture: COMPLETED
Registry last update: 2014-01-10

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of Langerhans cell histiocytosis, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may be an effective treatment for Langerhans cell histiocytosis. PURPOSE: This randomized clinical trial is studying combination chemotherapy to see how well it works in treating young patients with Langerhans cell histiocytosis.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part

eligibility Criteria: DISEASE CHARACTERISTICS: * Histopathologically confirmed diagnosis of Langerhans cell histiocytosis according to the criteria defined by the Histiocyte Society * Demonstration of CD1a antigenic determinants on the surface of lesional cells (by immunocytology or immunohistology) or Birbeck granules in lesional cells by electron microscopy * Considered at risk or low risk according to the following criteria: * Multi-system at risk disease, defined as involvement of one or more risk organs (i.e., hematopoietic system, liver, spleen, or lungs) * No single-system lung involvement * Multi-system low-risk disease * Multiple organs involved but without involvement of risk organs * Single-system disease * Multifocal bone disease (i.e., lesions in 2 or more different bones) * Localized special site involvement, such as CNS-risk lesions with intracranial soft tissue extension or vertebral lesions with intraspinal soft tissue extension * Vault lesions are not regarded as CNS-risk lesions PATIENT CHARACTERISTICS: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: * No prior treatment for Langerhans cell histiocytosis
healthy Volunteers: false
maximum Age: 17 Years
sex: ALL
std Ages: CHILD

Treatment arms and interventions

interventions

name
leucovorin calcium
type
DRUG
name
methotrexate
type
DRUG
name
prednisolone
type
DRUG
name
vinblastine sulfate
type
DRUG

Study design

allocation: RANDOMIZED
primary Purpose: TREATMENT

Enrollment

count: 376
type: ESTIMATED

Registered outcome plans (not posted results)

Full study description

brief Summary: RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of Langerhans cell histiocytosis, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may be an effective treatment for Langerhans cell histiocytosis. PURPOSE: This randomized clinical trial is studying combination chemotherapy to see how well it works in treating young patients with Langerhans cell histiocytosis.
detailed Description: OBJECTIVES: Primary * Compare the efficacy, in terms of response to initial therapy, of prednisolone, vinblastine, and mercaptopurine with vs without methotrexate and leucovorin calcium in young patients with Langerhans cell histiocytosis. * Compare the progression-free survival of patients with low-risk Langerhans cell histiocytosis who responded to initial therapy who are then treated with 6-month vs 12-month continuation therapy comprising prednisolone and vinblastine. Secondary * Compare the acute and long-term toxicity and the incidence of permanent effects. * Compare the overall and progression-free survival, response rate, and time until response. OUTLINE: This is a randomized, multicenter study with one pilot nonrandomized stratum. Patients are stratified according to number of systems involved (multiple vs single) and organs involved (at risk vs low risk). * Stratum 1 (at risk patients): Patients are further stratified according to participating center. Patients are randomized to 1 of 2 treatment arms (arms I and II). * Arm I: * Initial therapy: Patients receive oral prednisolone 3 times daily on days 1-28 followed by a taper on days 29-42 and vinblastine IV on days 1, 8, 15, 22, 29, and 36. Patients achieving nonactive disease (NAD) after course 1 proceed to continuation therapy. Patients achieving intermediate response or disease regression receive a second course\* of initial therapy. Patients achieving NAD or disease regression after course 2 proceed to continuation therapy. * Continuation therapy: Patients receive oral mercaptopurine daily for 3 weeks, pulsed oral prednisolone 3 times daily on days 1-5, and vinblastine IV on day 1. Treatment repeats every 3 weeks until day 365 from the beginning of therapy in the absence of disease progression or unacceptable toxicity. * Arm II: * Initial therapy: Patients receive prednisone and vinblastine as in arm I initial therapy. Patients also receive methotrexate IV over 24 hours on days 1, 15, and 29 and oral leucovorin calcium twice daily on days 2,16, and 30. Patients achieving NAD after course 1 proceed to continuation therapy. Patients achieving intermediate response or disease regression receive a second course\* of initial therapy. Patients achieving NAD or disease regression after course 2 proceed to continuation therapy. * Continuation therapy: Patients receive oral mercaptopurine daily for 3 weeks, pulsed oral prednisolone 3 times daily on days 1-5, vinblastine IV on day 1, and oral methotrexate on day 1. Treatment repeats every 3 weeks until day 365 from the beginning of therapy in the absence of disease progression or unacceptable toxicity. * Stratum 2 (low-risk patients): Patients are stratified according to age at diagnosis (≤ 2 vs \> 2) and participating center. Patients are randomized to 1 of 2 treatment arms (arms III and IV) after the first course of initial therapy. * Arm III: * Initial therapy: Patients receive prednisolone and vinblastine as in course 1 of stratum 1 arm I initial therapy. Patients achieving NAD or disease regression after course 1 proceed to continuation therapy. Patients achieving intermediate or worse response receive a second course\* of initial therapy. Patients achieving NAD, disease regression, or intermediate response after course 2 proceed to continuation therapy. * Continuation therapy: Patients receive prednisolone and vinblastine as in stratum 1 arm I continuation therapy. Treatment continues until day 182 from the beginning of initial therapy in the absence of disease progression or unacceptable toxicity. * Arm IV: * Initial therapy: Patients receive 1-2 courses of prednisolone and vinblastine as in stratum 2 arm III. * Continuation therapy: Patients receive pulsed prednisolone and vinblastine as in stratum 1 arm I continuation therapy. Treatment continues until day 365 from the beginning of initial therapy in the absence of disease progression or unacceptable toxicity. * Stratum 3 (pilot study) (patients with multifocal bone disease and/or special sites): * Initial therapy: Patients receive prednisolone and vinblastine as in stratum 1 arm I initial therapy. Patients achieving NAD or disease regression after course 1 proceed to continuation therapy. Patients with disease progression receive a second course\* of initial therapy. Patients achieving NAD or disease regression after course 2 proceed to continuation therapy. * Continuation therapy: Patients receive pulsed prednisolone and vinblastine as in stratum 1 arm I continuation therapy. Treatment continues until day 182 from the beginning of initial therapy in the absence of disease progression or unacceptable disease. NOTE: \*Patients receive oral prednisolone 3 times daily on days 43-45, 50-52, 57-59, 64-66, 71-73, and 78-80 only during the second course of initial therapy. After completion of study treatment, patients are followed periodically for 5 years. PROJECTED ACCRUAL: A total of 376 patients will be accrued for this study.

Source references

references

citation
Astigarraga I, Arnardottir H, Abla O, Arico M, Braier J, Donadieu J, Grois N, Henter JI, Ladisch S, Lehrnbecher T, McClain K, Nanduri V, Rodriguez-Galindo C, Sieni E, Weitzman S, Potschger U, Minkov M. Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis. Blood Adv. 2026 Jul 14;10(13):4776-4785. doi: 10.1182/bloodadvances.2026020075.
pmid
42101911
type
DERIVED
citation
Gadner H, Minkov M, Grois N, Potschger U, Thiem E, Arico M, Astigarraga I, Braier J, Donadieu J, Henter JI, Janka-Schaub G, McClain KL, Weitzman S, Windebank K, Ladisch S; Histiocyte Society. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013 Jun 20;121(25):5006-14. doi: 10.1182/blood-2012-09-455774. Epub 2013 Apr 15.
pmid
23589673
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-7ad944f6deaf1f5cd6122126
edge id
nct-edge-1a695326079457c885a3
requested nct id
NCT00276757
primary nct id
NCT00276757
source kind
nci_explicit_reference_or_link
source url
https://www.cancer.gov/types/langerhans/hp/langerhans-treatment-pdq
source record id
Source null
source file sha256
38648aea3a4c63acd4c5ebb70ec3d3016e515941db59b7036b7628a1a73c8f5e
payload sha256
f8084d0b6a49fc49a7cd927b003aa24a629ea7db9c0663118c53fb5c5f8e802e
payload
clinical indication matching status
not_inferred
end exclusive
true
id
nct-edge-1a695326079457c885a3
link basis
explicit_NCT_identifier_in_acquired_source
nct id
NCT00276757
occurrences
context exact
ren with LCH involving high-risk organs has improved.[<a href="#cit/section_3.27">27</a>,<a href="#cit/section_3.28">28</a>] Data from <a href="/clinicaltrials/NCT00276757">HISTSOC-LCH-III (NCT00276757)</a> showed an overall survival (OS) rate of 84% for patients treated for 12 months with systemic chemotherapy.[<a href="#cit/sec
end
91482
exact text
NCT00276757
start
91471
context exact
sk organs has improved.[<a href="#cit/section_3.27">27</a>,<a href="#cit/section_3.28">28</a>] Data from <a href="/clinicaltrials/NCT00276757">HISTSOC-LCH-III (NCT00276757)</a> showed an overall survival (OS) rate of 84% for patients treated for 12 months with systemic chemotherapy.[<a href="#cit/section_3.29">29</a>] 
end
91512
exact text
NCT00276757
start
91501
context exact
_3.73">73</a>] The incidence of diabetes insipidus was also lower in patients treated with more-intensive chemotherapy regimens on the <a href="/clinicaltrials/NCT00276757">HISTSOC-LCH-III (NCT00276757)</a>, JLSG-96, and JLSG-02 studies in Japan (8.9% for multisystem patients) compared with the HISTSOC-LCH-I and HISTSOC-LCH-II s
end
128733
exact text
NCT00276757
start
128722
context exact
f diabetes insipidus was also lower in patients treated with more-intensive chemotherapy regimens on the <a href="/clinicaltrials/NCT00276757">HISTSOC-LCH-III (NCT00276757)</a>, JLSG-96, and JLSG-02 studies in Japan (8.9% for multisystem patients) compared with the HISTSOC-LCH-I and HISTSOC-LCH-II studies (14.2%).[<a href="#cit/
end
128763
exact text
NCT00276757
start
128752
context exact
<li>Chemotherapy. The current treatment for CNS-risk bones is 12 months of vinblastine/prednisone therapy, as per the <a href="/clinicaltrials/NCT00276757">HISTSOC-LCH-III (NCT00276757)</a> study:[<a href="#cit/section_3.27">27</a>,<a href="#cit/section_3.29">29</a>][<a href="/Common/PopUps/popDefinition.aspx?id=
end
146139
exact text
NCT00276757
start
146128
context exact
ong> The current treatment for CNS-risk bones is 12 months of vinblastine/prednisone therapy, as per the <a href="/clinicaltrials/NCT00276757">HISTSOC-LCH-III (NCT00276757)</a> study:[<a href="#cit/section_3.27">27</a>,<a href="#cit/section_3.29">29</a>][<a href="/Common/PopUps/popDefinition.aspx?id=810025&version=HealthProfe
end
146169
exact text
NCT00276757
start
146158
context exact
ng> The most commonly used systemic chemotherapy regimen is the combination of vinblastine and prednisone. Based on the results of the <a href="/clinicaltrials/NCT00276757">HISTSOC-LCH-III (NCT00276757)</a> trial, 12 months of treatment with weekly vinblastine (6 mg/m2) for 7 weeks, then every 3 weeks, i
end
150836
exact text
NCT00276757
start
150825
context exact
temic chemotherapy regimen is the combination of vinblastine and prednisone. Based on the results of the <a href="/clinicaltrials/NCT00276757">HISTSOC-LCH-III (NCT00276757)</a> trial, 12 months of treatment with weekly vinblastine (6 mg/m2) for 7 weeks, then every 3 weeks, is used for good responders.[<a
end
150866
exact text
NCT00276757
start
150855
context exact
"><ol id="_1835"><li>Chemotherapy (vinblastine and prednisone in combination). Based on the results of the randomized <a href="/clinicaltrials/NCT00276757">HISTSOC-LCH-III (NCT00276757)</a> trial, the same chemotherapy regimen of vinblastine and prednisone, as described <a href="/types/langerhans/hp/langerhans-tr
end
152894
exact text
NCT00276757
start
152883
context exact
hemotherapy (vinblastine and prednisone in combination). Based on the results of the randomized <a href="/clinicaltrials/NCT00276757">HISTSOC-LCH-III (NCT00276757)</a> trial, the same chemotherapy regimen of vinblastine and prednisone, as described <a href="/types/langerhans/hp/langerhans-treatment-pdq#_1833">above</a>,
end
152924
exact text
NCT00276757
start
152913
context exact
1841" tabindex="-1">Evidence (chemotherapy): <div class="pdq-content-list"><ol id="_1842"><li> In the HISTSOC-LCH-II and <a href="/clinicaltrials/NCT00276757">HISTSOC-LCH-III (NCT00276757)</a> studies, the standard treatment arm consisted of vinblastine and prednisone, as described <a href="/types/langerhans/hp/lang
end
173501
exact text
NCT00276757
start
173490
context exact
chemotherapy): <div class="pdq-content-list"><ol id="_1842"><li> In the HISTSOC-LCH-II and <a href="/clinicaltrials/NCT00276757">HISTSOC-LCH-III (NCT00276757)</a> studies, the standard treatment arm consisted of vinblastine and prednisone, as described <a href="/types/langerhans/hp/langerhans-treatment-pdq#_1833">ab
end
173531
exact text
NCT00276757
start
173520
offset unit
unicode_code_points
source file
/tmp/cancer-full-research/nci/raw/ca4a4cd4123b612aa2.html
source file sha256
38648aea3a4c63acd4c5ebb70ec3d3016e515941db59b7036b7628a1a73c8f5e
source json pointer
Source null
source kind
nci_explicit_reference_or_link
source record id
Source null
source retrieved at
2026-09-09T23:21:52.461075+00:00
source string basis
UTF-8_text_with_universal_newline_translation
source string sha256
303ea1af9b4a6fa586761cb5df8b9d145dc97a62cfebcb7c74b226a8c763e10b
source title
Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version
source update dates
context
Updated: January 6, 2025
datetime
2025-01-06T12:00:00Z
display
January 6, 2025
source url
https://www.cancer.gov/types/langerhans/hp/langerhans-treatment-pdq

Preserved source evidence · Not medical advice